Skip to main content
XXII
NASDAQ Manufacturing

22nd Century Group's Q1 Revenue Plummets 31%, Flagship VLN® Sales Hit Zero Amid Widening Losses

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Industrial
Sentiment info
Negative
Importance info
9
Price
$0.842
Mkt Cap
$613.714K
52W Low
$0.79
52W High
$483
52W Position info
6.6% above low
Off High info
100% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

XXII is trading near its 52-week low of $0.79 (6.6% above the low).

Summary

22nd Century Group reported a sharp 31.1% year-over-year revenue decline to $4.1 million in Q1 2026, alongside widening operating losses and a critical $0.0 million in net revenue from its flagship VLN® cigarettes, intensifying concerns about its financial viability.


Key Events · Earnings and Guidance · XXII

  • Significant Revenue Decline

    Net revenues fell 31.1% year-over-year to $4.1 million for the first quarter ended March 31, 2026.

  • Worsening Profitability

    Operating loss increased to $3.0 million and Adjusted EBITDA loss widened to $2.6 million compared to the prior year quarter.

  • Zero VLN® Cigarette Revenue

    The company's flagship VLN® product recorded $0.0 million in net revenues for the quarter, following initial stocking orders in Q4 2025, offset by customer returns and product exchanges.

  • Cash Position Amid Dilution

    Ended the quarter with $9.5 million in cash and equivalents, against a backdrop of recently authorized highly dilutive At-The-Market offerings.


Analysis · XXII · Manufacturing

This 8-K filing reveals a deeply concerning financial performance for 22nd Century Group, with net revenues plummeting over 31% year-over-year and operating losses widening. Most critically, the company reported zero net revenue from its flagship VLN® cigarettes, a product central to its harm reduction strategy and future growth. These results significantly exacerbate the 'going concern' doubts previously disclosed in the company's 10-K and underscore the urgent need for the highly dilutive At-The-Market offerings recently authorized. Investors should view these results as a strong negative signal regarding the company's operational execution and financial stability, suggesting continued pressure on the stock.

At the time of this filing, XXII was trading at $0.84 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $613.7K. The 52-week trading range was $0.79 to $483.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XXII - Latest Insights

XXII
Jul 02, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.01
Real-time Price: $4.00 info
Change: -$0.0100 (-0.25%) info
Market Cap: $1.38M info
XXII
Jun 26, 2026, 4:15 PM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $3.93
Real-time Price: $4.00 info
Change: +$0.070 (+2%) info
Market Cap: $1.38M info
XXII
Jun 23, 2026, 5:23 PM EDT
Filing Type: DEF 14A
Importance Score:
10
Price at Filing: $4.70
Real-time Price: $4.00 info
Change: -$0.700 (-15%) info
Market Cap: $1.38M info
XXII
Jun 12, 2026, 5:15 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $6.52
Real-time Price: $4.00 info
Change: Reverse Stock Split info
Market Cap: $1.38M info
XXII
Jun 12, 2026, 5:00 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $6.51
Real-time Price: $4.00 info
Change: Reverse Stock Split info
Market Cap: $1.38M info